Share chart Lava Therapeutics B.V.
Extended chart
Simple chart
About Lava Therapeutics B.V.
Lava Therapeutics B.V., биотехнологическая компания, участвует в разработке портфеля биспецифических активаторов гамма-дельта Т-клеток (гамма-дельта-БСТКЭ) для лечения солидных опухолей и гематологических злокачественных новообразований на основе своей платформы. Его главный кандидат на продукт, LAVA-051, приближается к фазе 1 / 2a клинических испытаний для лечения гематологических опухолей, экспрессирующих CD1d, включая хронический лимфолейкоз, множественную миелому и острый миелоидный лейкоз. more details| IPO date | 2021-03-25 |
|---|---|
| ISIN | NL0015000AG6 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | http://www.lavatherapeutics.com |
| Цена ао | 1.29 |
| Change price per day: | -0.3876% (1.29) |
|---|---|
| Change price per week: | -2.65% (1.32) |
| Change price per month: | +36.7% (0.94) |
| Change price per 3 month: | +31.77% (0.9752) |
| Change price per half year: | -22.12% (1.65) |
| Change price per year: | -67.14% (3.91) |
| Change price per 3 year: | -70.05% (4.29) |
| Change price per year to date: | +29.8% (0.99) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Redmile Group, LLC | 2074372 | 7.89 |
| Novo Holdings A/S | 1878194 | 7.14 |
| Tang Capital Management, LLC | 840593 | 3.2 |
| Bruce & Co, Inc. | 771874 | 2.94 |
| Alpha Wave Global, LP | 107906 | 0.41 |
| PNC Financial Services Group, Inc. | 65000 | 0.25 |
| Millennium Management LLC | 28063 | 0.11 |
| Morgan Stanley | 24800 | 0.09 |
| Citadel Advisors Llc | 21552 | 0.08 |
| Tower Research Capital LLC (TRC) | 11460 | 0.04 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| AltShares Event-Driven ETF | 0.05021 | 9.61 | 1.21959 |
| 0.05 | 9.61 | 1.22 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Dr. Hans van der Vliet M.D., Ph.D. | Chief Scientific Officer | N/A | 1974 (51 year) |
| Mr. Stephen Allen Hurly M.B.A., M.Sc. | CEO, President & Executive Director | N/A | 1968 (57 years) |
| Mr. Wouter van Hunnik | VP & Head of Human Resources | N/A | |
| Ms. Amy Garabedian J.D. | General Counsel & Corporate Secretary | N/A | 1976 (49 years) |
| Dr. Ton Adang Ph.D. | Chief Development Officer | N/A | 1961 (64 years) |
| Mr. Fred M. Powell CPA | Chief Financial Officer | N/A | 1961 (64 years) |
| Dr. Charles Q. Morris M.D., MBChB, MRCP (UK), Ph.D. | Chief Medical Officer | N/A | 1965 (60 years) |
Address: Netherlands, Utrecht CM, Yalelaan 60 - open in Google maps, open in Yandex maps
Website: http://www.lavatherapeutics.com
Website: http://www.lavatherapeutics.com
